SCHEMBL19689787

SCHEMBL19689787

O=C(NC1CC1)N1c2nc(-c3cccc(C(F)(F)F)c3)ccc2N2CC[C@H]1C2

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.43
▸ MAOA P21397 3/20 0.43
▸ MAOB P27338 3/20 0.43
▸ RPS6KB1 P23443 1/20 0.41
▸ IDH2 P48735 4/20 0.41
▸ ALDH1A1 P00352 2/20 0.39
▸ GRIN1 Q05586 2/20 0.39
▸ GRIN2B Q13224 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ KIT P10721 1/20 0.39
▸ KMO O15229 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PAK1 Q13153 1/20 0.38
▸ NOTUM Q6P988 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19689810 0.96 ALDH1A1 (0.42) KDM1AMAOAMAOBRPS6KB1IDH2
SCHEMBL19699711 0.96 ALDH1A1 (0.44) KDM1AMAOAMAOBRPS6KB1IDH2
SCHEMBL17768313 0.96 ALDH1A1 (0.44) KDM1AMAOAMAOBRPS6KB1IDH2
SCHEMBL17768083 0.96 ALDH1A1 (0.43) KDM1AMAOAMAOBRPS6KB1IDH2
SCHEMBL19689772 0.90 CNR2 (0.43) KDM1AMAOAMAOBIDH2ALDH1A1
SCHEMBL17778800 0.88 CSNK1E (0.41) KDM1AMAOAMAOBIDH2ALDH1A1
SCHEMBL17618783 0.88 MEN1 (0.47) IDH2ALDH1A1KITMEN1KMT2A
SCHEMBL17618383 0.88 CNR2 (0.41) KDM1AIDH2ALDH1A1CYP2C19KCNH2
SCHEMBL19689756 0.88 KMT2A (0.41) KDM1AMAOAMAOBIDH2ALDH1A1
SCHEMBL17618348 0.88 IDH2 (0.45) IDH2ALDH1A1GRIN2BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-14 — — US disclosed
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-14 — — US disclosed
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 KDM1A 903/4885MAOA 1153/4885MAOB 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback